Compare SMSI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMSI | MRKR |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7M | 19.5M |
| IPO Year | 2017 | 2010 |
| Metric | SMSI | MRKR |
|---|---|---|
| Price | $2.67 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 14.3K | ★ 53.7K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.94 | 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,363,000.00 | N/A |
| Revenue This Year | $13.97 | N/A |
| Revenue Next Year | $53.35 | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.84 |
| 52 Week High | $6.13 | $2.46 |
| Indicator | SMSI | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 50.72 |
| Support Level | $2.66 | $1.08 |
| Resistance Level | $3.03 | $1.31 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 17.53 | 48.28 |
Smith Micro Software Inc provides software solutions that simplify and enhance the mobile experience to some of the wireless service providers around the globe. The company's solutions include SafePath product suite provides comprehensive and easy-to-use tools to protect family digital lifestyles and manage connected devices both inside and outside the home; CommSuite premium messaging platform helps mobile service providers deliver a next-generation voicemail experience to mobile subscribers, while monetizing a legacy cost-center; and ViewSpot its retail display management platform provided wireless carriers and retailers with a way to bring powerful on-screen, interactive demos to life. It operates in single segment: Wireless.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).